A2. Commits to comply with human rights standards in product development & marketing
T1. Publishes its R&D costs.
T2. Publishes its profit margin.
T3. The company publishes the average and/or marginal costs of production.
T4. Publishes its production capacity.
T5. The company publishes the public subsidies it received during product development and/or testing
T6. Publishes the text of licensing agreements.
T7. Registers its clinical trials in public repositories.
C1. The company commits to C-TAP or MPP
C2. Commits to not enforcing the exclusive rights of Covid-19 related patents.
C3. Supplies to, or signs agreements with, the vaccines or therapeutics pillar of the ACT Accelerator.
E1. The company makes the active ingredient available on reasonable grounds. [ therapeutics only]
E2. Commits to full technology transfer to other manufacturers.
E3. Commits to non-profit or ‘fair’ pricing.
E6. Agrees to waive exclusive rights in regulatory test data [where applicable].
E4. Equitably distributes supplies globally. [vaccines only]
E5. The company does not seek protection beyond the minimum criteria in TRIPS, or enforces TRIPS+ measures [where applicable]
A1. Publishes a global access plan for its product.